CORTIVAZOL--PHASE I TRIAL IN PATIENTS WITH INCURABLE MALIGNANCIES

考替伐唑——针对无法治愈的恶性肿瘤患者的 I 期试验

• 批准号: 6246340
• 负责人: E B THOMPSON
• 金额: $ 2.71万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-06 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246340
• 关键词: antineoplastics; clinical research; clinical trial phase I; drug screening /evaluation; glucocorticoids; human subject; human therapy evaluation; neoplasm /cancer; neoplasm /cancer chemotherapy

A phase I clinical oncology trial of cortivazol, a potent glucocorticoid, in patients with various malignancies is proposed. The purpose of the study is to determine the toxicity and maximum tolerated dose (MTD) of cortivazol in humans. Cortivazol in DMSO solution will be given to patients intravenously on a schedule of 5 days on/9 days off. The doses will increase until MTD is reached.

Cortivazol的I期临床肿瘤学试验，这是一种有效的 糖皮质激素是针对各种恶性肿瘤的患者。这 研究的目的是确定毒性和最大耐受性 人类Cortivazol的剂量（MTD）。 DMSO溶液中的皮尔蒂瓦唑将是 在休息时间为5天的时间表，请静脉内给予患者。 剂量将增加，直到达到MTD。